Several studies using the FDA adverse event reporting system (FAERS) database have demonstrated that bevacizumab combined with PD-1 monoclonal antibody increases the risk of serious adverse effects such as fever, physical condition deterioration, thrombocytopenia, bone marrow failure, and neutropenia in oncology patients [59, 60]. This evidence concerns the gene PDCD1 and Thrombocytopenia.